880 related articles for article (PubMed ID: 10341273)
1. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
Furtado MR; Callaway DS; Phair JP; Kunstman KJ; Stanton JL; Macken CA; Perelson AS; Wolinsky SM
N Engl J Med; 1999 May; 340(21):1614-22. PubMed ID: 10341273
[TBL] [Abstract][Full Text] [Related]
2. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
Zhang L; Ramratnam B; Tenner-Racz K; He Y; Vesanen M; Lewin S; Talal A; Racz P; Perelson AS; Korber BT; Markowitz M; Ho DD
N Engl J Med; 1999 May; 340(21):1605-13. PubMed ID: 10341272
[TBL] [Abstract][Full Text] [Related]
3. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy.
Zhang H; Dornadula G; Beumont M; Livornese L; Van Uitert B; Henning K; Pomerantz RJ
N Engl J Med; 1998 Dec; 339(25):1803-9. PubMed ID: 9854115
[TBL] [Abstract][Full Text] [Related]
4. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
Deeks SG; Wrin T; Liegler T; Hoh R; Hayden M; Barbour JD; Hellmann NS; Petropoulos CJ; McCune JM; Hellerstein MK; Grant RM
N Engl J Med; 2001 Feb; 344(7):472-80. PubMed ID: 11172188
[TBL] [Abstract][Full Text] [Related]
5. Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy.
Carr JM; Cheney KM; Coolen C; Davis A; Shaw D; Ferguson W; Chang G; Higgins G; Burrell C; Li P
J Clin Microbiol; 2007 Apr; 45(4):1288-97. PubMed ID: 17314225
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients.
Re MC; Vitone F; Biagetti C; Schiavone P; Alessandrini F; Bon I; de Crignis E; Gibellini D
Clin Microbiol Infect; 2010 Jun; 16(6):640-6. PubMed ID: 19732081
[TBL] [Abstract][Full Text] [Related]
8. Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy.
Vitone F; Gibellini D; Schiavone P; Re MC
J Clin Virol; 2005 Jul; 33(3):194-200. PubMed ID: 15911440
[TBL] [Abstract][Full Text] [Related]
9. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
10. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy.
Günthard HF; Wong JK; Spina CA; Ignacio C; Kwok S; Christopherson C; Hwang J; Haubrich R; Havlir D; Richman DD
J Infect Dis; 2000 Feb; 181(2):522-31. PubMed ID: 10669335
[TBL] [Abstract][Full Text] [Related]
11. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
12. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of cell-free and cell-associated peripheral blood human immunodeficiency virus type 1 RNA response to antiretroviral therapy.
Romano L; Venturi G; Catucci M; De Milito A; Valensin PE; Zazzi M
J Infect Dis; 1999 Feb; 179(2):361-6. PubMed ID: 9878019
[TBL] [Abstract][Full Text] [Related]
14. Steady increase in cellular HIV-1 load during the asymptomatic phase of untreated infection despite stable plasma viremia.
Pasternak AO; Jurriaans S; Bakker M; Berkhout B; Lukashov VV
AIDS; 2010 Jul; 24(11):1641-9. PubMed ID: 20543660
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy.
Imamichi H; Crandall KA; Natarajan V; Jiang MK; Dewar RL; Berg S; Gaddam A; Bosche M; Metcalf JA; Davey RT; Lane HC
J Infect Dis; 2001 Jan; 183(1):36-50. PubMed ID: 11106537
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 DNA and RNA kinetics in primary HIV infection.
Lillo F; Grasso M; Lodini S; Capiluppi B; Lazzarin A; Tambussi G
J Biol Regul Homeost Agents; 2002; 16(1):49-52. PubMed ID: 12003174
[TBL] [Abstract][Full Text] [Related]
17. Different patterns of HIV-1 DNA after therapy discontinuation.
Re MC; Vitone F; Sighinolfi L; Schiavone P; Ghinelli F; Gibellini D
BMC Infect Dis; 2005 Sep; 5():69. PubMed ID: 16156892
[TBL] [Abstract][Full Text] [Related]
18. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V
Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540
[TBL] [Abstract][Full Text] [Related]
19. Human immunodeficiency virus type-1 mRNA splicing pattern in infected persons is determined by the proportion of newly infected cells.
Vesanen M; Markowitz M; Cao Y; Ho DD; Saksela K
Virology; 1997 Sep; 236(1):104-9. PubMed ID: 9299622
[TBL] [Abstract][Full Text] [Related]
20. Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.
Nicastri E; Tommasi C; Abbate I; Bonora S; Tempestilli M; Bellagamba R; Viscione M; Rozera G; Gallo AL; Ivanovic J; Amendola A; Pucillo L; Di Perri G; Capobianchi MR; Narciso P
Antivir Ther; 2011; 16(6):797-803. PubMed ID: 21900711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]